YUNNAN BAIYAO(SZ:000538)2025-04-11 09:24Financial Performance - In 2024, the company achieved operating revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - Net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - Non-recurring net profit attributable to shareholders was 4.523 billion CNY, a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, growing by 22.68% [3] - The weighted average return on net assets was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share rose to 2.66 CNY, a 16.16% increase [3] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total operating revenue, with an industrial revenue growth rate of 5.30% [3] - Industrial gross margin improved to 65.93%, up 1.69 percentage points [3] - Sales expenses decreased by 2.26% year-on-year, while management expenses fell by 1.98% [3] Pharmaceutical Business Performance - The pharmaceutical business group reported main business revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [4] - Sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [4] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing 200 million CNY, up over 22% [4] Traditional Chinese Medicine Industry Development - The company is leading the development of Yunnan's traditional Chinese medicine industry, focusing on seed industry, planting, processing, and branding [5][6] - Established Yunnan Baiyao Group Seed Technology Co., Ltd. for seed quality control [6] - The processing platform in Lijiang achieved a production increase of 180% [6] - The "Smart Cloud Medicine" platform launched, facilitating over 100 million CNY in transactions [6] Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved main business revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [7] - Non-drug business sectors like medical devices and special medical foods saw a sales increase of 14% [8] - The OTC sector experienced a sales growth of 18%, while new specialty drug pharmacies grew by 29% [8]